MetaCap

Lakefront Biotherapeutics (LKFT) vs Arcus Biosciences (RCUS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Lakefront Biotherapeutics (LKFT) has outperformed Arcus Biosciences (RCUS) over the past year, gaining 8.6% versus a loss of 29.2%. Over five years, LKFT leads with a -31.8% price change compared with -66.3% for RCUS. Arcus Biosciences is the larger company by market cap ($2.25 billion vs $2.18 billion), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

LKFT+8.64%RCUS-29.16%
+47%+7%-33%
Nov 21, 20251 yearNov 20, 2026
LKFT-35.27%RCUS-67.15%
+42%-25%-92%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

LKFT versus RCUS key metrics
MetricLKFTRCUS
Share price$33.31$15.62
Market cap$2.18B$2.25B
1-day change-0.24%-1.01%
YTD return+1.87%-34.45%
1-year return+8.64%-29.16%
5-year return-31.80%-66.31%
P/E ratio (TTM)2.39—
EPS (TTM)$13.94$-3.64
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$247.00M
Revenue growth (YoY)—-4.26%
Net income (latest FY)—$-353.00M
Operating margin—-156.28%
Net margin—-142.91%
52-week high$36.24$31.74
52-week low$25.68$15.56
Distance from 52-week high-8.08%-50.78%
Analyst consensusholdstrong_buy
Avg. price target upside-7.39%+162.48%
Average volume280.49K1.85M
Shares outstanding65.48M143.99M
Employees196601
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • LKFT has outperformed RCUS by 37.8 percentage points over the past year.

About Lakefront Biotherapeutics

LKFT stock →

Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.

Health Care · Biotechnology: Pharmaceutical Preparations · 196 employees

About Arcus Biosciences

RCUS stock →

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody.

Health Care · Biotechnology: Pharmaceutical Preparations · 601 employees

LKFT vs RCUS FAQ

Which is bigger, Lakefront Biotherapeutics or Arcus Biosciences?

Arcus Biosciences (RCUS) is larger, with a market capitalization of $2.25B compared with $2.18B for Lakefront Biotherapeutics (LKFT).

Which stock has performed better over the past year, LKFT or RCUS?

LKFT returned +8.64% over the past 12 months, compared with -29.16% for RCUS (price return, excluding dividends). Past performance does not predict future results.

Are Lakefront Biotherapeutics and Arcus Biosciences in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons